Entry249.15→Now259.36
J&J pullback is a buying chance Open original source
JNJ Johnson & Johnson Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
23:15
Oct 20
Oct 20
CNBC
Buy JNJ for AAA balance sheet.
Cramer says young investors can buy Johnson & Johnson as a healthcare holding because it has an AAA balance sheet, which he calls perhaps the only one.
JNJ
Johnson & Johnson
Long
—
—
23:50
Oct 13
Oct 13
CNBC
J&J pullback is a buying chance
Cramer thinks J&J's post-earnings drop is unwarranted because the quarter was fine. Revenue and EPS beat, U.S. sales were strong, and innovative medicine did well, led by Tremfya and a new oral plaque psoriasis pill, with mid-teens oncology growth and strong neuroscience. Medtech was light but has bright spots. J&J raised full-year guidance, plans to spin off its DePuy Synthes orthopedics business, trades near 20 times next year's earnings, yields 2.2% and has a top S&P credit rating. He calls the pullback a good chance to buy ahead of the December 8 investor day.
JNJ
Johnson & Johnson
Long
2ND
Position: Holding
—
About JNJ Investor Commentary
Across the available history and selected sources, Buzzberg tracks JNJ (Johnson & Johnson) across 40 sources: 63 bullish vs 0 bearish calls from 62 authors. Historical directional balance: 35% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 180 total trade ideas tracked. Past 7 days, before deduplication: 1 bullish, 5 other directions. Latest voices: Jim Cramer.